Introduction: amplification is a known resistance mechanism to tyrosine kinase inhibitor (TKI) treatment in -mutant NSCLC. Dual EGFR-MET inhibition has been reported with success in overcoming such resistance and inducing clinical benefit. Resistance mechanisms to dual EGFR-MET inhibition require further investigation and characterization.
View Article and Find Full Text PDFPurpose: In head and neck squamous cell carcinoma (HNSCC), mutation is a new actionable oncogene driver. We aimed to evaluate mutational variants, comutation profile, and survival outcomes of this molecularly defined population.
Methods: We leveraged four deidentified patient data sets with -mutant HNSCC, MD Anderson Cancer Center, Kura Oncology, Inc trial, Foundation Medicine, and American Association for Cancer Research GENIE v.
Background: The benefit of chemotherapy combined with immunotherapy in EGFR-mutant lung adenocarcinoma (LUAD) patients whose tumor developed resistance to EGFR tyrosine kinase inhibitors (TKIs) is not thoroughly investigated. The goal of this retrospective cohort study is to assess the clinical efficiency of immunotherapy alone or in combination with chemotherapy in a real-world setting.
Methods: This retrospective cohort study enrolled LUAD patients with EGFR sensitive mutations whose tumor had acquired resistance to EGFR TKIs and received systemic treatment with chemotherapy (chemo; = 84), chemotherapy combined with immunotherapy (chemoIO; = 30), chemotherapy plus bevacizumab with or without IO (withBev; = 42), and IO monotherapy (IO-mono; = 22).
Purpose: Neoadjuvant chemotherapy prior to definitive surgery has been utilized widely for locally advanced oral squamous cell carcinoma (OSCC). We evaluated neoadjuvant erlotinib with platinum-docetaxel vs. placebo with platinum-docetaxel in stage III-IVB OSCC patients.
View Article and Find Full Text PDF© LitMetric 2025. All rights reserved.